T. Rowe Price Associates’s Pear Therapeutics, Inc. Class A Common Stock PEAR Stock Holding History

T. Rowe Price Associates’s Portfolio PEAR Stock Details PEAR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-11,499	Closed	-$3K	–	3036
2023 Q1	$3K	Hold	11,499	–	–	﹤0.01%	2919
2022 Q4	$14K	Buy	11,499 +1,099	+11%	+$2.31K	﹤0.01%	2889
2022 Q3	$22K	Buy	+10,400	New	+$17.6K	﹤0.01%	2910

T. Rowe Price Associates's PEAR Position: Q2 2023 in Review

T. Rowe Price Associates sold out of Pear Therapeutics, Inc. Class A Common Stock (PEAR) in Q2 2023, closing a stake of 11,499 shares — an estimated $3K sold.

T. Rowe Price Associates first reported a position in PEAR in Q3 2022 and held it in 3 quarters. The position peaked at $22K in Q3 2022. 1 fund tracked by Wall St. Rank holds PEAR as of Q2 2023.

T. Rowe Price Associates reported no remaining Pear Therapeutics, Inc. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
T. Rowe Price Associates sold 11,499 Pear Therapeutics, Inc. Class A Common Stock shares in Q2 2023, an estimated $3K.
T. Rowe Price Associates first reported a position in Pear Therapeutics, Inc. Class A Common Stock in Q3 2022 and held it in 3 quarters.
T. Rowe Price Associates's Pear Therapeutics, Inc. Class A Common Stock position peaked at $22K in Q3 2022.
1 fund tracked by Wall St. Rank held Pear Therapeutics, Inc. Class A Common Stock as of Q2 2023.

Based on T. Rowe Price Associates's 13F filing for Q2 2023, filed 14 Aug 2023.